Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sublingual bivalent vaccination with PspA-C-CPE and Alcaligenes lipid A induces protective immunity against both Streptococcus pneumoniae and Clostridium perfringens.

Research square·2026
Same author

Targeting claudins in cancer.

Nature reviews. Drug discovery·2026
Same author

Balancing Multivalent Avidity and Receptor Availability Governs mRNA Delivery by Antibody-Functionalized Lipid Nanoparticles.

Nano letters·2026
Same author

Aryl Hydrocarbon Receptor-Mediated Disruption of Intestinal Epithelial Barrier Integrity by Dioxin Isomers.

Toxics·2025
Same author

Overview of the Japanese Rapid Introduction Premium as a drug pricing framework to enhance patient access to innovative drugs.

Health economics review·2025
Same author

Flavivirus-based bivalent nanoparticle vaccines induce neutralizing antibodies and Th1 responses against flavivirus and coupling antigens.

iScience·2025

Related Experiment Video

Updated: Jun 13, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Mucosal vaccination using claudin-4-targeting.

Hideki Kakutani1, Masuo Kondoh, Masahiro Fukasaka

  • 1Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan.

Biomaterials
|April 20, 2010
PubMed
Summary

Targeting claudin-4 with a fusion protein (OVA-C-CPE) effectively enhances mucosal immune responses. This novel nasal vaccination strategy shows promise for inducing antigen-specific antibodies and anti-tumor activity.

More Related Videos

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jun 13, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • Mucosa-associated lymphoid tissue (MALT) is crucial for mucosal immunity.
  • Efficient antigen delivery to MALT is key for mucosal vaccine development.
  • Claudin-4, expressed in gut MALT, has not been utilized for mucosal vaccination.

Purpose of the Study:

  • To investigate claudin-4 expression in nasal MALT.
  • To develop and evaluate a claudin-4-targeting fusion protein for nasal vaccination.
  • To assess the efficacy of this strategy in inducing immune responses and anti-tumor activity.

Main Methods:

  • Prepared a fusion protein (OVA-C-CPE) linking ovalbumin (OVA) antigen with a claudin-4 binder (C-CPE).
  • Administered OVA-C-CPE via nasal immunization in a mouse model.
  • Assessed antigen-specific serum IgG, IgA (nasal, vaginal, fecal), Th1/Th2 responses, and anti-tumor activity.

Main Results:

  • Claudin-4 is expressed in nasal MALT.
  • Nasal immunization with OVA-C-CPE, but not OVA + C-CPE, induced OVA-specific IgG and IgA.
  • Immune response induction was dependent on the claudin-4-binding region.
  • OVA-C-CPE immunization activated Th1 and Th2 responses and demonstrated anti-tumor effects.

Conclusions:

  • Claudin-4 targeting is a potent strategy for nasal vaccination.
  • The developed fusion protein effectively delivers antigens to nasal MALT.
  • This approach holds potential for developing new mucosal vaccines.